BioSpace News Archive

Immune-Onc Therapeutics, Inc. (“Immune-Onc”),today announced that two abstracts on IO-108, a novel myeloid checkpoint inhibitor targeting Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4), were accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting.

Nuvectis Pharma, Inc. announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 34th Annual Roth Conference.

Global research report called Advanced Process Control (APC) market was recently published by Reports and Data. to provide guidance for the business.

Top companies in the market are focusing on R&D activities to expand their product offerings and cater to unmet medical needs of the global population.

The industry analysis report is considered a valuable source of information about the global Nanoparticle Drug Delivery Systems industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The report highlights the growth opportunities and challenges that industry players might encounter in the forecast years, along with an elaborate competitive landscape and expansion strategies adopted by the companies functioning in the Pharmaceutical Labeling Market.

The industry analysis report is considered a valuable source of information about the global Sinus Dilation Device industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The industry analysis report is considered a valuable source of information about the global Tinea Pedis Treatment industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announces today that Erica Monaco, Chief Executive Officer, will be presenting and meeting with registered investors at the 34th Annual Roth Conference being held March 13-15 in Laguna Niguel, California.

Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that it has received FDA approval of two pivotal investigational device exemptions (IDE) for its Exablate Neuro system – one for primary non-small cell lung cancer (NSCLC) that has metastasized to the brain in conjunction with standard-of-care Keytruda®.